Circulogene Theranostics, founded with a mission to revolutionize cancer diagnostics, specializes in cfDNA analysis, liquid biopsies, and tumor monitoring. The company offers proprietary laboratory-developed tests for cfDNA, cRNA, and MSI liquid biopsies, utilizing next-generation sequencing (NGS) to provide comprehensive genomic load analysis from a single blood sample within a week. Their services aim to deliver precise data to clinicians, enabling personalized and targeted cancer therapies, ultimately improving patient outcomes.

Notable figures affiliated with Circulogene include leading experts in molecular diagnostics and oncology. The company has attracted significant investment from stakeholders interested in advancing cancer diagnostics. Key achievements include the development of their innovative liquid biopsy tests, which have been instrumental in aiding oncologists to tailor and monitor treatment plans effectively. Circulogene's impact is evident in its contribution to more personalized cancer care, offering a less invasive and faster alternative to traditional biopsy methods.